What is MRNA's five-year median P/S?

3.7x. Half of MRNA's weekly readings over the last five years were higher and half were lower. This page has 287 weekly readings, from May 3, 2021 to Oct 26, 2026.

Does a low historical rank mean a stock is a buy?

No. The rank compares MRNA only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.

Moderna (MRNA) valuation

Health Care

$222.76

Latest weekly close · Market cap $88.7B

Historically high

Moderna's P/S of 39.8x is higher than 99% of its weekly readings over the last five years (as of Oct 30, 2026).

No P/E: earnings over the last twelve months are negative.
No EV/EBITDA: recent financial data is missing.

Weekly P/S with its 5-year range

P/S each weekMiddle half of the last 5 years5-year median 3.7×

5-year median: 3.7×
10-year median: 4.1×
5-year low to high: 2.2× to 40.2×
Versus 5-year median: +964%

P/S

99thpercentile

of its weekly readings over the last five years

Growth, last 12 months vs the year before

Revenue: -28%accelerating
EPS: n/m

Price vs revenue and EPS, indexed to 100

Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.

PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading

P/S at each year-end

The last weekly reading of each year, and its percentile against the five years before it.

MRNA P/S at each year-end
Year-end	P/S	5-year percentile	P/E	EV/Sales	EV/EBITDA
Dec 29, 2025	5.4×	71	n/m	3.4×	n/m
Dec 30, 2024	3.3×	29	n/m	2.0×	n/m
Dec 25, 2023	4.2×	69	n/m	3.3×	n/m
Dec 26, 2022	3.5×	40	6.5×	3.1×	4.8×
Dec 27, 2021	9.3×	10	15.6×	8.6×	13.0×

Health Care peers on P/S

Each percentile compares a stock with its own last five years.

Compare MRNA with peers

Health Care peers of MRNA on P/S
Stock	P/S	Versus its own history	5-year percentile
ABBVAbbVie	8.0×	Historically high	100
AMGNAmgen	6.6×	Historically high	100
ARWRArrowhead Pharmaceuticals Inc	13.0×	Within its usual range	37
BIIBBiogen	3.6×	Above its usual range	75
BMRNBioMarin Pharmaceutical Inc	3.3×	Historically low	3

Appears in

Sector: Health Care
Screens: Nuclear Stocks: Valuation Screen
Semiconductor Equipment Stocks: Valuation Screen

Screen Health Care stocks the same way

Research on MRNA

No articles about MRNA yet. How valuation percentiles work

Loading peers and related research…

About this history

What is MRNA's current P/S?: Moderna's P/S of 39.8x is higher than 99% of its weekly readings over the last five years (as of Oct 30, 2026).
What is MRNA's five-year median P/S?: 3.7x. Half of MRNA's weekly readings over the last five years were higher and half were lower. This page has 287 weekly readings, from May 3, 2021 to Oct 26, 2026.
Does a low historical rank mean a stock is a buy?: No. The rank compares MRNA only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.